Nuvalent Reports the US FDA’s NDA Submission for Neladalkib to Treat ALK-Positive NSCLC

Why It Matters

The NDA positions neladalkib to become one of the few options for patients who have exhausted multiple ALK‑TKIs, potentially reshaping the treatment algorithm for advanced ALK‑positive NSCLC and creating a new revenue stream for Nuvalent.

Key Takeaways

• NDA filed for neladalkib targeting TKI‑pretreated ALK‑positive NSCLC.
• ALKOVE‑1 trial showed intracranial responses and manageable safety.
• Drug holds FDA breakthrough therapy and orphan designations.
• Addresses unmet need after ≥2 prior ALK‑TKI therapies.
• Potential to expand treatment options for advanced lung cancer.

Pulse Analysis

The landscape for ALK‑positive non‑small cell lung cancer has evolved dramatically over the past decade, driven by a succession of targeted tyrosine‑kinase inhibitors. While first‑line agents such as alectinib and brigatinib deliver high response rates, resistance inevitably emerges, leaving patients who have failed two or more ALK‑TKIs with limited therapeutic choices. This gap has spurred intense research into next‑generation inhibitors that can overcome resistance mechanisms and penetrate the blood‑brain barrier, a critical factor given the high incidence of brain metastases in this population.

Neladalkib, Nuvalent’s investigational ALK‑selective molecule, is designed to inhibit a broad spectrum of ALK resistance mutations while maintaining central nervous system exposure. The Phase I/II ALKOVE‑1 trial enrolled heavily pre‑treated patients and reported encouraging overall response rates, including durable intracranial responses, and a safety profile comparable to existing agents. These data earned the drug both breakthrough therapy and orphan drug designations from the FDA, signaling regulatory confidence in its potential to fulfill an unmet medical need and expediting its review pathway.

If approved, neladalkib could become a pivotal line of therapy after failure of at least two prior ALK‑TKIs, expanding the treatment arsenal for oncologists and offering hope to a patient cohort with few alternatives. The submission also highlights Nuvalent’s strategic focus on niche oncology indications, which may attract partnership interest or bolster its valuation. Investors will watch forthcoming conference presentations and the FDA’s decision timeline closely, as the outcome could influence competitive dynamics among established players and emerging biotech firms in the ALK‑positive lung cancer space.